SmartTRAK reports that with new products providing a strong tailwind in Q318, the SCS market saw another quarter of strong double-digit growth in both the US and WW, positioning the market for another record year.
- Market Overview
Abbott’s Slowdown Continues
- What’s Next?
Boston Scientific Going Strong on WaveWriter
- DBS Ramping Up
- Nevro’s Growth Decelerates
A Skeptical Wall Street
Strategies for Growth
Q318 Regulatory and Clinical Highlights
According to SmartTRAK, YTD in 2018, the US SCS market grew +21.1% vs the same time period in 2017 , while the WW SCS market reached...